JP2016525114A5 - - Google Patents

Claims (9)

A combination comprising an NS5A targeting compound and an NS5A synergist, which when administered results in synergistic anti-HCV activity against a mutant comprising a mutation that confers resistance only to the NS5A targeting compound; The NS5A synergist has the formula (I):

[Where
R ¹ ′ and R ¹ ′ are independently selected from alkoxyalkyl, alkyl, cycloalkyl and pyranyl, wherein the cycloalkyl and pyranyl are optionally independently of alkyl, halo, haloalkyl, hydroxy and hydroxyalkyl. Optionally substituted by 1, 2 or 3 selected substituents; and
R ² and R ² ′ are the same or different alkyl groups]
Or a pharmaceutically acceptable salt thereof. The compound of formula (I) is

The combination according to claim 1, which is a compound of formula (I) selected from: or a pharmaceutically acceptable salt thereof. A composition comprising the combination according to claim 1 or 2 and one or more pharmaceutically acceptable carriers.   4. The composition of claim 3, further comprising one or two other compounds having anti-HCV activity.   5. The composition of claim 4, wherein at least one of the other compounds is interferon or ribavirin.   6. The composition according to claim 5, wherein the interferon is selected from interferon α2B, pegylated interferon α, pegylated interferon λ, consensus interferon, interferon α2A or lymphoblastoid interferon τ.   At least one other compound is a target selected from HCV protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein or IMPDH for the treatment of HCV infection 5. The composition of claim 4, which is effective to inhibit function. A composition according to any one of claims 3-7 for the treatment of HCV infection in patients. One or two additional compounds having anti-HCV activity, before Ri case combination of claim 1 or 2, and after, or feature to be used for administration at the same time, one of the claims 4-8 the composition according to any.